Multiple myeloma patients have an increased risk of infections due to both the inherent nature of the disease and ongoing treatment. We describe the case of a patient who was treated with daratumumab-lenalidomide-dexamethasone regimen for two years and developed a parvovirus B19 infection. The clinical picture, characterized by trilinear cytopenia, was initially attributed to anti-neoplastic treatment. Later on, when the patient’s condition worsened, an extensive diagnostic workup was applied and parvovirus B19 infection was detected by PCR. Due to the lack of effective antiviral drugs, the patient received IV immunoglobulins and it took 10 days to achieve a decrease in viral copies. Physicians should be aware that recent changes in the therapeutic scenario of multiple myeloma would make patients more susceptible to atypical infections in this patient setting.

Case report: Unexpected parvovirus B19 infection in a myeloma patient treated with daratumumab / Palazzo, M., Ciolli, G., Pilerci, S., Attucci, I., Pengue, L., Vannucchi, A.M., Antonioli, E.. - In: FRONTIERS IN HEMATOLOGY. - ISSN 2813-3935. - ELETTRONICO. - 1:(2022), pp. 1035281.1-1035281.5. [10.3389/frhem.2022.1035281]

Case report: Unexpected parvovirus B19 infection in a myeloma patient treated with daratumumab

Palazzo, Marianna;Ciolli, Gaia;Pilerci, Sofia;Attucci, Irene;Pengue, Ludovica;Vannucchi, Alessandro Maria;Antonioli, Elisabetta
2022

Abstract

Multiple myeloma patients have an increased risk of infections due to both the inherent nature of the disease and ongoing treatment. We describe the case of a patient who was treated with daratumumab-lenalidomide-dexamethasone regimen for two years and developed a parvovirus B19 infection. The clinical picture, characterized by trilinear cytopenia, was initially attributed to anti-neoplastic treatment. Later on, when the patient’s condition worsened, an extensive diagnostic workup was applied and parvovirus B19 infection was detected by PCR. Due to the lack of effective antiviral drugs, the patient received IV immunoglobulins and it took 10 days to achieve a decrease in viral copies. Physicians should be aware that recent changes in the therapeutic scenario of multiple myeloma would make patients more susceptible to atypical infections in this patient setting.
2022
1
1
5
Goal 3: Good health and well-being
Palazzo, Marianna; Ciolli, Gaia; Pilerci, Sofia; Attucci, Irene; Pengue, Ludovica; Vannucchi, Alessandro Maria; Antonioli, Elisabetta
File in questo prodotto:
File Dimensione Formato  
frhem-01-1035281.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 437.3 kB
Formato Adobe PDF
437.3 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1500373
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact